Zydus Lifesciences · NSE: ZYDUSLIFE · BSE: 532321

Q4 FY21 results · Jan–Mar 2021

Zydus Lifesciences reported revenue from operations of ₹3,846.70 crore (up 2.5% from Q4 FY20) and net profit of ₹735.40 crore (up 77.8% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY21	Q4 FY20	YoY	Q3 FY21	QoQ
Revenue from operations	3,846.70	3,752.10	+2.5%	3,795.60	+1.3%
Other income	(40.30)	44.30	Turned loss	27.50	Turned loss
Total income	3,806.40	3,796.40	+0.3%	3,823.10	−0.4%
Profit before share of associates & JVs and tax	530.00	522.00	+1.5%	627.20	−15.5%
Share of profit/(loss) of associates & JVs	3.80	0.20		15.50
Net profit for the period	735.40	413.70	+77.8%	528.00	+39.3%
Attributable to shareholders of the company	679.00	391.90	+73.3%	527.20	+28.8%
EPS, basic (₹)	6.63	3.83	+73.1%	5.15	+28.7%
Net margin (%)	19.1	11.0		13.9

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY21	Q4 FY20	YoY	Q3 FY21	QoQ
Revenue from operations	2,018.80	1,812.20	+11.4%	1,918.80	+5.2%
Other income	(26.90)	400.20	Turned loss	25.00	Turned loss
Total income	1,991.90	2,212.40	−10.0%	1,943.80	+2.5%
Profit before tax	441.80	692.90	−36.2%	206.90	+113.5%
Net profit for the period	464.70	619.30	−25.0%	140.30	+231.2%
EPS, basic (₹)	4.54	6.05	−25.0%	1.37	+231.4%
Net margin (%)	23.0	34.2		7.3

Consolidated

Filed with BSE: 27 May 2021, 15:31 IST
Board meeting: 27 May 2021
Period: 01 Jan 2021 to 31 Mar 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 27 May 2021, 15:31 IST
Board meeting: 27 May 2021
Period: 01 Jan 2021 to 31 Mar 2021
Review status: Unaudited
Source: XBRL filing on BSE